Prospective Exploratory Study of a Multiomic Blood Biomarker Panel to Predict Chemotherapy-Induced Peripheral Neuropathy (CIPN)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: longitudinal blood sampling and standardized neurological evaluation over 6 months.
- Who it may be relevant to
- Registry conditions: Chemotherapy Induced Neuropathic Pain, Neuropathy Toxic, Taxane-induced Peripheral Neuropathy, Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The goal of this prospective, multicenter, observational cohort study with longitudinal blood sampling and standardized neurological evaluation over 6 months is to identify biomarkers to predict the overall occurrence of chronic chemotherapy-induced peripheral neuropathy (CIPN, any grade), in each of two treatment subgroups (taxanes and oxaliplatin). It involves integration of clinical data and plasma multiomic biomarkers (proteomic + metabolomic panel) analyzed via supervised machine learning to identify predictive features of CIPN.
Detailed description
In this prospective exploratory cohort study based on artificial intelligence data analysis, we aim to identify useful markers to predict the occurrence of CIPN in patients receiving taxanes or oxaliplatin to treat their cancers.
We plan to recruit 192 consecutive patients from 2 hospitals (Hôpital Forcilles and Centre Hospitalier de Bligny) treated for cancer, aimed to receive a prolonged treatment (9 weeks or more) with a neurotoxic drug: taxanes (subgroup 1: 78 patients), and oxaliplatin (subgroup 2: 114 patients). Study design is built to detect promising markers (including biomarkers from our exclusive panel) possibly linked to neuropathy that could help predict its occurrence and clinically meaningful impact. A balanced selection was made to enable the collection of as much information as possible while limiting the impact on patients. Patients will be included before treatment and follow-up will last 6 months after start of treatment.
Interventions
- Diagnostic test longitudinal blood sampling and standardized neurological evaluation over 6 months
Prospective, multicenter, observational cohort study with longitudinal blood sampling and standardized neurological evaluation over 6 months
Primary outcome measures
- Neuropathy prediction [Time frame: From enrollment to 6 months after.]
Secondary outcome measures (2)
- Neuropathy severity prediction [Time frame: From enrollment to 6 months after]
- Time to onset of chronic neuropathy [Time frame: from enrollment to 6 months after]
Eligibility criteria
Inclusion criteria
- Patients who have received detailed information about the study and have signed, with the investigator, a consent form to participate in the study
- Patients being treated for cancer at any stage of the disease and scheduled to receive chemotherapy including one (and only one) of the following molecules: paclitaxel, docetaxel, or oxaliplatin, for a planned duration of 9 weeks or more
- Age > 18 years
- Life expectancy > 3 months
- Patient affiliated with or entitled to social security
Exclusion criteria
- Patients already suffering from neuropathy or chronic neurogenic pain
- Patients with type 1 or type 2 diabetes (for more than 10 years for type 2 diabetes)
- Patients who have already received neurotoxic cancer treatment including those in clinical trials
- Patients receiving two of the study molecules simultaneously (only one study molecule is permitted, including in combination chemotherapy but that does not include another neurotoxic molecule)
- Patients receiving immunotherapy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07511569 · 2026-001